This comprehensive assessment forms the foundation for developing an individualized treatment plan that may include behavioral interventions, nutritional counseling, exercise prescription, psychological support, and increasingly, pharmacologic therapy
Our study reports real-world outcomes in a responder-defined T2D cohort treated at variable doses including lower doses
Note: Tirzepatide is the only one of these medications that is both a GLP-1 and GIP agonist
However, supraphysiological levels of GLP-1 (brought about by infusion) may increase glucose-stimulated insulin secretion to levels similar to those of control subjects receiving glucose alone [5]
V., Stornaiuolo, A., Cretella, G., Miele, A., Giannini, C., & De Simone, R
Allow us to take you back to middle school science class for a minute